Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment, A Phase II Study | MicrobiomeTrials
Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment, A Phase II Study
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-04-14Est. Completion: 2027-12-30
Enrollment target: 33 participants
Locations
Renmin Hospital of Wuhan University, Wuhan, Hubei, China